Compare Recursion Pharmaceuticals Inc (RXRX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Wheaton Precious Metals Corp trades at $157.31 (market cap $70.35B). The key difference: Wheaton Precious Metals Corp is far larger — about 37.8× Recursion Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.5% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WPM | |
|---|---|---|
Market Cap | $1.86B | $70.35B |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $165.72 |
52-Week Low | $2.84 | $94.37 |
Enterprise Value | $1.38B | $72.23B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $1.19 versus $1.15 expected, and record revenue of $2.31 billion in 2025 underscore robust operational momentum. The company's royalty and streaming model continues to deliver high margins, with a net income margin of 64.66% in 2025.
The outlook remains positive, supported by an 80% analyst buy rating and a consensus price target of $161.75, though risks include exposure to commodity price volatility and significant capital expenditures projected for 2026. The stock's current valuation multiples, such as a P/E of 34.41, reflect premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
